Original ArticleAdjuvant Chemotherapy for Stage II Colon Cancer: Practice Patterns and Effectiveness in the General Population
Introduction
International guidelines do not recommend adjuvant chemotherapy (ACT) for stage II colon cancer [1], [2], [3]. The pivotal IMPACT meta-analysis reported that ACT improved overall survival in stage III (hazard ratio 0.70, 95% confidence interval 0.53–0.92) but not stage II colon cancer (hazard ratio 0.91, 95% confidence interval 0.63–1.34) [4]. The lack of benefit in stage II disease was confirmed in the follow-up IMPACT B2 meta-analysis and two subsequent meta-analyses [5], [6], [7]. However, international guidelines acknowledge that there are subgroups of stage II colon cancer that are at high risk of disease relapse. On the basis of this higher risk of recurrent disease, guidelines state that ACT may be considered in patients with T4 tumours, poorly differentiated histology, inadequate nodal harvest, perforation/obstruction, lymphovascular invasion or perineural invasion [1], [2], [3]. However, there is no strong evidence upon which to base this recommendation.
It is well known that clinical practice may not mirror evidence and guideline recommendations. Population-based studies provide insight into practice and outcomes in routine clinical practice [8], [9]. By including all cases within a given jurisdiction, these studies minimise selection bias and referral bias that plague traditional institution-based case series. Although a number of studies have previously described the use of ACT for stage II colon cancer in the general population, with one exception [10], these studies are all from the USA [11], [12], [13], [14], [15], [16], [17]. Moreover, several of these studies used the linked SEER-Medicare database and were therefore restricted to patients older than 65 years [11], [14], [15]. Across these studies, ACT utilisation rates for stage II colon cancer ranged from 12 to 38%. Several population-based reports have evaluated the association between ACT and overall survival of stage II colon cancer with mixed results [10], [11], [12], [14], [15], [16]. Only one of these studies evaluated disease-specific survival; it found an association between ACT and overall survival but not disease-specific survival [10]. Given the limitations of the existing literature and the ongoing debate regarding the role of ACT in stage II colon cancer, we undertook a population-based study with the following objectives: (i) to describe the use of ACT for stage II colon cancer; and (ii) to evaluate the effectiveness of ACT for stage II disease (with and without high-risk pathological features).
Section snippets
Study Design and Population
This was a population-based, retrospective cohort study to describe the management and outcome of resected stage II colon cancer in the Canadian province of Ontario. Ontario has a population of about 13.5 million people and a single-payer universal health insurance programme. The study population included patients who underwent resection of stage II colon cancer in Ontario between 2002 and 2008 and survived >30 days after surgery. To identify the study cohort we used the Ontario Cancer Registry
Study Population
Linked administrative datasets identified 25 613 potentially eligible patients who underwent resection of primary colon cancer in 2002–2008 (Figure 1). Surgical pathology reports were reviewed for 7519 randomly selected cases. The age, gender, comorbidity and survival of these randomly selected cases did not differ substantially from the 18 094 unselected cases (Supplementary Table S1, Figure S1). Among the 7519 randomly selected cases, 270 (4%) were excluded, as shown in Figure 1. Among 2599
Discussion
Here we describe the use and effectiveness of ACT for stage II colon cancer in the general population. Several important findings have emerged. First, ACT utilisation rates are 24 and 14% for those patients with, and without, high-risk pathological features. These treatment rates are considerably lower than those reported in the USA. Second, ACT utilisation varies considerably across age groups and geographical regions. Notably, ACT was delivered to 42% of patients aged 20–49 years without
Acknowledgements
The authors gratefully acknowledge the contributions of Tina Dyer, Susan Rohland, Sarah Pickett and Lois Bulch in the conduct of this study. Parts of this material are based on data and information provided by Cancer Care Ontario. However, the analysis, conclusions, opinions and statements expressed herein are those of the authors and not necessarily those of Cancer Care Ontario. This study was supported by the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual
References (29)
- et al.
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Ann Oncol
(2013) - et al.
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases
J Clin Epidemiol
(1992) - et al.
American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer
J Clin Oncol
(2004) NCCN Guidelines Colon Cancer
(2015)Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
Lancet
(1995)Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer
J Clin Oncol
(1999)- et al.
Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
J Clin Oncol
(2004) - et al.
Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group
J Clin Oncol
(2004) - et al.
Translating new medical therapies into societal benefit: the role of population-based outcome studies
JAMA
(2008) - et al.
Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence
Br J Cancer
(2014)
Adjuvant chemotherapy use and outcomes of patients with high-risk versus low-risk stage II colon cancer
Cancer
Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data
Ann Surg Oncol
Association between adherence to National Comprehensive Cancer Network treatment guidelines and improved survival in patients with colon cancer
Cancer
Adherence to stage-specific treatment guidelines for patients with colon cancer
J Clin Oncol
Cited by (30)
Genome-wide identification and analysis of prognostic features in human cancers
2022, Cell ReportsCitation Excerpt :Finally, we found that classifying patients based on single features identified through this analysis was sufficient to distinguish outcomes in ambiguous clinical situations where patients are at risk of undertreatment or overtreatment. This includes stage 1A breast cancer (Elias, 2012), stage 2 colon cancer (Booth et al., 2017; Lee et al., 2019), and Gleason 7 prostate cancer (Srigley et al., 2019; Stark et al., 2009) (Figure 3B). When the expression or mutation of a gene is found to be associated with poor patient prognosis, this is typically presented as evidence that that gene is an important driver of disease progression (Kaelin, 2017).
Development of a Risk Score and Nomogram to Predict Individual Benefit Attained from the Addition of Adjuvant Chemotherapy in the Treatment of Stage II Colon Cancer
2021, Journal of Gastrointestinal SurgeryBenefit of adjuvant chemotherapy in high-risk colon cancer: A 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer
2020, European Journal of CancerCitation Excerpt :The study by Kumar et al. identified T4 status as the only high-risk factor with a constant and significant benefit in OS, RFS, and DSS [7]. However, other reports do not support these findings, e.g. an analysis based on the Surveillance, Epidemiology, and End Results (SEER) Program data set including 24,847 patients with UICC stage II colon carcinoma or a recent evaluation of the Ontario Cancer Registry [9, 15]. In addition, a meta-analysis of 12 clinical trials estimates the benefit to OS of UICC stage II high-risk patients at 2–4%, an advantage so small that the authors discourage the use of adjuvant chemotherapy in UICC stage II [16].
Combination of multiple tumor-infiltrating immune cells predicts clinical outcome in colon cancer
2020, Clinical ImmunologyCitation Excerpt :Colon cancer is one of the most commonly occurring and leading death malignant tumor with 101,420 new cancer cases and 51,020 cancer deaths in the United States 2019 [11,12]. Previous studies have focused on molecular markers and adjuvant chemotherapy (ACT) hoping to improve the survival of patient with colon cancer [13–16]. Here, to find a new prognostic signature to improve the overall survival of colon cancer patients, we constructed the immune cell infiltrating profile of samples based on estimating relative subsets of RNA transcripts (CIBERSORT) algorithm [9] and identified a multiple-immune cells infiltrating signature which could predict the survival in a large scale of 879 patients with colon cancer.
Overuse and Limited Benefit of Chemotherapy for Stage II Colon Cancer in Young Patients
2019, Clinical Colorectal CancerThe use of chemotherapy in older patients with stage II and III colon cancer: Variation by age and era of diagnosis
2019, Journal of Geriatric Oncology